Moleculin Biotech Inc. (MBRX)
Moleculin Announces Completion of Treatment for the 45 Patients in Pivotal "MIRACLE" Phase 3 AML Trial on Pace for Q1 2026
Moleculin Announces Completion of Treatment for the 45 Patients in Pivotal "MIRACLE" Phase 3 AML Trial on Pace for Q1 2026
📊 **NEUTRAL** • Medium confidence analysis (70%) • Weak clinical signals • Minimal impact anticipated **Sentiment:** Neutral (50%) **Content type:** Clinical